2026 Q2 -tulosraportti
1 päivä sitten
‧45 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 25.8. | ||
2026 Q1 -tulosraportti 22.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenEdvard hall has held a Q&A session for investors. This recording discusses both pre-submitted questions and describes the current status in ongoing sales projects. https://youtu.be/CpNa1cIzT6o?is=s-nXIArZ64FwRddT
·10 t sitten · MuokattuImpressed that the stock is holding up. Short-term, the stock price is a coin-flip, based on what comes first, a deal or a share issue. (And is the deal, which most likely comes within 4 weeks, of such a size that investors will participate in a share issue at a higher price?)The agreements that are underway are very price-driving, and for the Kemi project agreement, which is one of the closest, there is already a framework agreement. Kemi is a very large company, and it has always taken a lot of time to get internal approvals on agreements.- ·20.8.The CEO's message Formal start of the project with the customer in Western Asia In May, we announced that our partner, Chematur Engineering, had entered into a binding agreement with a customer in Western Asia regarding the first large-scale PHBV plant based on Bioextrax's patented technology. After the end of the second quarter, the customer made the agreed advance payment. The agreement has thereby entered into force, and Phase 1 – the basic design of the plant – has formally commenced. The work is estimated to take five months, and in parallel, the agreement for Phase 2, which includes detailed design, construction, and commissioning of the factory, is being finalized. Progress in the collaboration with Kemiföretaget Another important step was taken at the end of June, when we reached an agreement with Kemiföretaget – one of the world's three largest chemical companies – on a binding framework agreement. The agreement was signed at the beginning of July, runs for three years with the possibility of extension, and creates a clear structure for joint innovation and commercialization projects within Home & Personal Care. The first project concerns mcl-PHA as a bio-based and biodegradable film former that can replace, for example, silicone in personal care products. The driving force in the application is clear: the EU's restrictions against intentionally added microplastics mean that the industry needs alternatives that both function technically and degrade naturally. Strong interest in sun protection Within cosmetics, the sun protection track, which I wrote about in the previous report, has also been further developed. Our early results indicate that our PHBV has a better enhancing effect on SPF (sun protection factor, solskyddsfaktor) compared to PHA from other players, and this has continued to attract interest. Since the previous report, further dialogues and concrete tests have been initiated with global players. Sunscreen is an application that combines requirements from legislators, large volumes, and good willingness to pay, and we continue to evaluate it together with a growing circle of potential customers. Update on the project with Godisproducenten Regarding the collaboration with Godisproducenten, which aims to replace traditional polymers in chewing gums with biodegradable alternatives, we were recently informed that a major reorganization is underway within Godisproducenten. This, in turn, means that the test panel planned for the second quarter of 2026 has been delayed. Currently, we do not know when the test panel will be carried out. Ongoing production for Lantmännen In the project with Lantmännen, a large part of our work in recent months has focused on getting the entire production system in place – not just the hydrolysis step itself, which is the core of our technology, but also the downstream steps such as separation and drying. This is a prerequisite for being able to produce the quantities of hydrolyzed protein required by the feeding trials, and it has required significant resources to get all parts to work together. That work has now been completed. Our focus is therefore on finalizing production so that the material can proceed to feed mixing and feeding trials, together with Lantmännen. News regarding R&D In parallel with commercial development, we have developed a new technology for the production of PHBV, for which we have submitted a patent application. For natural reasons, we are not going into any details at this time, but we see significant potential in it and will revert when the patent situation allows. Continuously broadening and strengthening our intellectual property portfolio is central to a business model based on out-licensing. Ultimately, it is the patents that constitute the product we sell, and every new application that holds increases the value of what we have to offer future licensees. During the period, we have also installed our own laboratory for strain development and commenced work there. Strain development involves developing and refining the microorganisms that produce our PHA, and this gives us significantly greater flexibility – both to influence the material properties of the PHA produced and to adapt the process parameters in production. This opens up the possibility of meeting specific customer requirements in a way that would otherwise not have been possible. In parallel, we continue to develop our existing production processes based on so-called “wild bacteria”; the new laboratory complements this work, it does not replace it. Lund, August 20, 2026 Edvard Hall Managing Director
·14.8.The company is currently small, has few employees, but has groundbreaking technology. A breakthrough here means contracts that are enormously large in SEK compared to today's market value. The stock is a binary bet currently, where the value might halve if things continue to drag out, but where the upside is 5-10x when concrete agreements come. The first agreement with "Kemi-bolaget" should be right around the corner.Market worth at 100 million then you are relatively cautious with 5x on the upside. I don't think there's much downside either with valuation against market value, probably scraping the bottom. I don't foresee another 50% 7 days before an update on projects. Rather listen to the podcast, However, I'm not all in, only a relatively small position.- ·13.8.https://open.spotify.com/episode/1jlEKFgYJBoZ6zgj9qbrKD https://open.spotify.com/episode/1jlEKFgYJBoZ6zgj9qbrKD New podcast episode with Edward today.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
1 päivä sitten
‧45 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenEdvard hall has held a Q&A session for investors. This recording discusses both pre-submitted questions and describes the current status in ongoing sales projects. https://youtu.be/CpNa1cIzT6o?is=s-nXIArZ64FwRddT
- ·10 t sitten · MuokattuImpressed that the stock is holding up. Short-term, the stock price is a coin-flip, based on what comes first, a deal or a share issue. (And is the deal, which most likely comes within 4 weeks, of such a size that investors will participate in a share issue at a higher price?)The agreements that are underway are very price-driving, and for the Kemi project agreement, which is one of the closest, there is already a framework agreement. Kemi is a very large company, and it has always taken a lot of time to get internal approvals on agreements.
- ·20.8.The CEO's message Formal start of the project with the customer in Western Asia In May, we announced that our partner, Chematur Engineering, had entered into a binding agreement with a customer in Western Asia regarding the first large-scale PHBV plant based on Bioextrax's patented technology. After the end of the second quarter, the customer made the agreed advance payment. The agreement has thereby entered into force, and Phase 1 – the basic design of the plant – has formally commenced. The work is estimated to take five months, and in parallel, the agreement for Phase 2, which includes detailed design, construction, and commissioning of the factory, is being finalized. Progress in the collaboration with Kemiföretaget Another important step was taken at the end of June, when we reached an agreement with Kemiföretaget – one of the world's three largest chemical companies – on a binding framework agreement. The agreement was signed at the beginning of July, runs for three years with the possibility of extension, and creates a clear structure for joint innovation and commercialization projects within Home & Personal Care. The first project concerns mcl-PHA as a bio-based and biodegradable film former that can replace, for example, silicone in personal care products. The driving force in the application is clear: the EU's restrictions against intentionally added microplastics mean that the industry needs alternatives that both function technically and degrade naturally. Strong interest in sun protection Within cosmetics, the sun protection track, which I wrote about in the previous report, has also been further developed. Our early results indicate that our PHBV has a better enhancing effect on SPF (sun protection factor, solskyddsfaktor) compared to PHA from other players, and this has continued to attract interest. Since the previous report, further dialogues and concrete tests have been initiated with global players. Sunscreen is an application that combines requirements from legislators, large volumes, and good willingness to pay, and we continue to evaluate it together with a growing circle of potential customers. Update on the project with Godisproducenten Regarding the collaboration with Godisproducenten, which aims to replace traditional polymers in chewing gums with biodegradable alternatives, we were recently informed that a major reorganization is underway within Godisproducenten. This, in turn, means that the test panel planned for the second quarter of 2026 has been delayed. Currently, we do not know when the test panel will be carried out. Ongoing production for Lantmännen In the project with Lantmännen, a large part of our work in recent months has focused on getting the entire production system in place – not just the hydrolysis step itself, which is the core of our technology, but also the downstream steps such as separation and drying. This is a prerequisite for being able to produce the quantities of hydrolyzed protein required by the feeding trials, and it has required significant resources to get all parts to work together. That work has now been completed. Our focus is therefore on finalizing production so that the material can proceed to feed mixing and feeding trials, together with Lantmännen. News regarding R&D In parallel with commercial development, we have developed a new technology for the production of PHBV, for which we have submitted a patent application. For natural reasons, we are not going into any details at this time, but we see significant potential in it and will revert when the patent situation allows. Continuously broadening and strengthening our intellectual property portfolio is central to a business model based on out-licensing. Ultimately, it is the patents that constitute the product we sell, and every new application that holds increases the value of what we have to offer future licensees. During the period, we have also installed our own laboratory for strain development and commenced work there. Strain development involves developing and refining the microorganisms that produce our PHA, and this gives us significantly greater flexibility – both to influence the material properties of the PHA produced and to adapt the process parameters in production. This opens up the possibility of meeting specific customer requirements in a way that would otherwise not have been possible. In parallel, we continue to develop our existing production processes based on so-called “wild bacteria”; the new laboratory complements this work, it does not replace it. Lund, August 20, 2026 Edvard Hall Managing Director
- ·14.8.The company is currently small, has few employees, but has groundbreaking technology. A breakthrough here means contracts that are enormously large in SEK compared to today's market value. The stock is a binary bet currently, where the value might halve if things continue to drag out, but where the upside is 5-10x when concrete agreements come. The first agreement with "Kemi-bolaget" should be right around the corner.Market worth at 100 million then you are relatively cautious with 5x on the upside. I don't think there's much downside either with valuation against market value, probably scraping the bottom. I don't foresee another 50% 7 days before an update on projects. Rather listen to the podcast, However, I'm not all in, only a relatively small position.
- ·13.8.https://open.spotify.com/episode/1jlEKFgYJBoZ6zgj9qbrKD https://open.spotify.com/episode/1jlEKFgYJBoZ6zgj9qbrKD New podcast episode with Edward today.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 25.8. | ||
2026 Q1 -tulosraportti 22.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
2026 Q2 -tulosraportti
1 päivä sitten
‧45 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 25.8. | ||
2026 Q1 -tulosraportti 22.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenEdvard hall has held a Q&A session for investors. This recording discusses both pre-submitted questions and describes the current status in ongoing sales projects. https://youtu.be/CpNa1cIzT6o?is=s-nXIArZ64FwRddT
- ·10 t sitten · MuokattuImpressed that the stock is holding up. Short-term, the stock price is a coin-flip, based on what comes first, a deal or a share issue. (And is the deal, which most likely comes within 4 weeks, of such a size that investors will participate in a share issue at a higher price?)The agreements that are underway are very price-driving, and for the Kemi project agreement, which is one of the closest, there is already a framework agreement. Kemi is a very large company, and it has always taken a lot of time to get internal approvals on agreements.
- ·20.8.The CEO's message Formal start of the project with the customer in Western Asia In May, we announced that our partner, Chematur Engineering, had entered into a binding agreement with a customer in Western Asia regarding the first large-scale PHBV plant based on Bioextrax's patented technology. After the end of the second quarter, the customer made the agreed advance payment. The agreement has thereby entered into force, and Phase 1 – the basic design of the plant – has formally commenced. The work is estimated to take five months, and in parallel, the agreement for Phase 2, which includes detailed design, construction, and commissioning of the factory, is being finalized. Progress in the collaboration with Kemiföretaget Another important step was taken at the end of June, when we reached an agreement with Kemiföretaget – one of the world's three largest chemical companies – on a binding framework agreement. The agreement was signed at the beginning of July, runs for three years with the possibility of extension, and creates a clear structure for joint innovation and commercialization projects within Home & Personal Care. The first project concerns mcl-PHA as a bio-based and biodegradable film former that can replace, for example, silicone in personal care products. The driving force in the application is clear: the EU's restrictions against intentionally added microplastics mean that the industry needs alternatives that both function technically and degrade naturally. Strong interest in sun protection Within cosmetics, the sun protection track, which I wrote about in the previous report, has also been further developed. Our early results indicate that our PHBV has a better enhancing effect on SPF (sun protection factor, solskyddsfaktor) compared to PHA from other players, and this has continued to attract interest. Since the previous report, further dialogues and concrete tests have been initiated with global players. Sunscreen is an application that combines requirements from legislators, large volumes, and good willingness to pay, and we continue to evaluate it together with a growing circle of potential customers. Update on the project with Godisproducenten Regarding the collaboration with Godisproducenten, which aims to replace traditional polymers in chewing gums with biodegradable alternatives, we were recently informed that a major reorganization is underway within Godisproducenten. This, in turn, means that the test panel planned for the second quarter of 2026 has been delayed. Currently, we do not know when the test panel will be carried out. Ongoing production for Lantmännen In the project with Lantmännen, a large part of our work in recent months has focused on getting the entire production system in place – not just the hydrolysis step itself, which is the core of our technology, but also the downstream steps such as separation and drying. This is a prerequisite for being able to produce the quantities of hydrolyzed protein required by the feeding trials, and it has required significant resources to get all parts to work together. That work has now been completed. Our focus is therefore on finalizing production so that the material can proceed to feed mixing and feeding trials, together with Lantmännen. News regarding R&D In parallel with commercial development, we have developed a new technology for the production of PHBV, for which we have submitted a patent application. For natural reasons, we are not going into any details at this time, but we see significant potential in it and will revert when the patent situation allows. Continuously broadening and strengthening our intellectual property portfolio is central to a business model based on out-licensing. Ultimately, it is the patents that constitute the product we sell, and every new application that holds increases the value of what we have to offer future licensees. During the period, we have also installed our own laboratory for strain development and commenced work there. Strain development involves developing and refining the microorganisms that produce our PHA, and this gives us significantly greater flexibility – both to influence the material properties of the PHA produced and to adapt the process parameters in production. This opens up the possibility of meeting specific customer requirements in a way that would otherwise not have been possible. In parallel, we continue to develop our existing production processes based on so-called “wild bacteria”; the new laboratory complements this work, it does not replace it. Lund, August 20, 2026 Edvard Hall Managing Director
- ·14.8.The company is currently small, has few employees, but has groundbreaking technology. A breakthrough here means contracts that are enormously large in SEK compared to today's market value. The stock is a binary bet currently, where the value might halve if things continue to drag out, but where the upside is 5-10x when concrete agreements come. The first agreement with "Kemi-bolaget" should be right around the corner.Market worth at 100 million then you are relatively cautious with 5x on the upside. I don't think there's much downside either with valuation against market value, probably scraping the bottom. I don't foresee another 50% 7 days before an update on projects. Rather listen to the podcast, However, I'm not all in, only a relatively small position.
- ·13.8.https://open.spotify.com/episode/1jlEKFgYJBoZ6zgj9qbrKD https://open.spotify.com/episode/1jlEKFgYJBoZ6zgj9qbrKD New podcast episode with Edward today.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt